Abstracts tagged "antiphospholipid syndrome"

Abstract Number: 1556 • ACR Convergence 2024
Efficacy and Safety of Anifrolumab Across Organ Domains of Systemic Lupus Erythematosus. A Systematic Review and Meta-Analysis
Mohammad Taha¹, Yomna W Mahmoud¹, Mohammad Ramadan¹, sarah nasir¹, Mariam salah¹, Yassin shenawy², doaa gadelrab¹ and Muhammad abuawwad¹, and ARC team, ¹Cairo university, Cairo, Egypt, ²cairo, cairo, Egypt

Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting multiple organ systems. Anifrolumab is a monoclonal antibody that antagonizes type I interferon receptors,…
Abstract Number: 0111 • ACR Convergence 2024
Comparative Performance of ELISA and CLIA Against the 2023 ACR/EULAR APS Classification Criteria
Polona Zigon¹, Nika Bostič¹, Ziga Rotar², Ales Ambrozic³, Elizabeta Blokar³, Manca ogrič¹ and Sasa Cucnik¹, ¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ²University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, ³Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana
Background/Purpose: Recently published 2023 ACR/EULAR APS classification criteria emphasize delineating moderate/high anticardiolipin (aCL) and anti-β2 glycoprotein I (anti-β2GPI) antibodies. The new criteria specify the use…
Abstract Number: 0127 • ACR Convergence 2024
Unsupervised Machine Learning Improves Clinical Stratification and Prognostic Evaluation for Antiphospholipid Syndrome: A Large Cohort Study from China
Chen Chen¹, Ao Zhang², Jianhui Cheng³, Zhongqiang Yao⁴, Juan Meng⁵, Yilu Qin⁶, Qingyi Lu¹, Yufei Li¹, Xiangjun Liu¹, Tianhao Li⁷, Chao Hou⁷, Yundi Tang¹, Hongjiang Liu⁸, Ning Xu¹, Sai Dong¹, Xinxin Li³, Fangmin Xu², Jianping Guo¹ and Chun Li¹, ¹Peking University People's Hospital, Beijing, China, ²Beijing University of Posts and Telecommunications, Beijing, China, ³State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, China (People's Republic), ⁴Peking University Third Hospital, Beijing, China, ⁵Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing, China, ⁶Affiliated Xinxiang Central Hospital of Xinxiang Medical University, Xinxiang, China (People's Republic), ⁷Peking University Health Science Center, Beijing, China, ⁸West China Hospital, Sichuan University, Chengdu, China (People's Republic)
Background/Purpose: Antiphospholipid syndrome (APS) is a complex disease characterized by the presence of anti-phospholipid antibodies (aPLs). Its significant clinical heterogeneity brings clinical and therapeutical challenges.…
Abstract Number: 1702 • ACR Convergence 2024
Placental Developmental Defects in a Humanized-TLR8 Mouse Model of Spontaneous Anti-Phospholipid Antibody Induced Pregnancy Loss
Yunwei Xia¹, Naomi I. Maria², Zhengzi Yi³, Chirag Raparia⁴, Gayathri Konanur Gopikrishna¹, Weijia Zhang³ and Anne Davidson², ¹Feinstein Institutes for Medical Research, Manhasset, ²Feinstein Institutes for Medical Research, Manhasset, NY, ³Mt. Sinai School of Medicine, New York, NY, ⁴Donald and Barbara Zucker School of Medicine At Hofstra/Northwell, Shoreham, NY
Background/Purpose: Antiphospholipid antibodies (aPL) confer a high risk for adverse pregnancy outcomes, especially in women with SLE. aPLs can induce pro-inflammatory signaling via TLR8 receptors,…
Abstract Number: 0096 • ACR Convergence 2023
Performance Assessment of Lupus Anticoagulant Tests Using Taipan and Ecarin Snake Venom Clotting Times: An International Study from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Core Laboratories
Maria Efthymiou¹, Ian Mackie¹, Rohan Willis², Vittorio Pengo³, Danieli Andrade⁴, Elisa Bison³, Olga Amengual⁵, Zurina Romay-Penabad⁶, Yuichiro Fujieda⁵, Maria Laura Bertolaccini⁷, Doruk Erkan⁸, Hannah Cohen⁹ and On Behalf Of APS ACTION¹⁰, ¹University College London, London, United Kingdom, ²University of Texas Medical Branch, Galveston, TX, ³Department of Cardiac-Thoracic-Vascular Sciences and Public Health University of Padova, Padova, Italy, ⁴University of São Paulo, São Paulo, Brazil, ⁵Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Sapporo, Japan, ⁶Antiphospholipid Standardization Laboratory, Division of Rheumatology, University of Texas Medical Branch, TX, ⁷King's College London, London, United Kingdom, ⁸Hospital for Special Surgery, New York, NY, ⁹University College London Hospitals NHS Foundation Trust, London, United Kingdom, ¹⁰on behalf of APS ACTION, New York, NY
Background/Purpose: Lupus anticoagulant (LA) test performance is critical for APS diagnosis and management. However, variability remains a challenge in LA testing, particularly in anticoagulated samples,…
Abstract Number: 0112 • ACR Convergence 2023
Molecular Stratification of Antiphospholipid Syndrome Patients Through Integrative Analysis of the Whole-blood RNA Transcriptome
Amala Ambati¹, Feiyang Ma¹, Katarina Kmetova¹, Sherwin Navaz¹, Claire Hoy¹, Cyrus Sarosh¹, Ajay Tambralli¹, Johann E. Gudjonsson¹, J. Michelle Kahlenberg¹, Jacqueline Madison¹, Ali Duarte-Garcia², Jason Knight¹ and Yu Zuo¹, ¹University of Michigan, Ann Arbor, MI, ²Mayo Clinic, Rochester, MN
Background/Purpose: Antiphospholipid syndrome (APS) is an acquired thrombo-inflammatory disease associated with diverse clinical manifestations in the setting of persistent antiphospholipid antibodies (aPL). Early diagnosis and…
Abstract Number: 2324 • ACR Convergence 2023
Leveraging ChatGPT for Real-World Systematic Lupus Erythematosus Data Curation from Electronic Health Records: A Feasibility Study
Lixia Yao, Liwam Gebru, Biruk Aweke, Jay Patel, Ernest Vina, David Fleece and Huanmei Wu, Temple University, Philadelphia, PA
Background/Purpose: Epidemiologists, health services researchers, and health outcome investigators have begun utilizing real-world data (RWD) to gain valuable insights into disease patterns, treatment outcomes, and…
Abstract Number: 0097 • ACR Convergence 2023
Transient Ischemic Attack in Antiphospholipid Antibody-positive Patients: Retrospective and Prospective Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Zeynep Belce Erton¹, Jonathan Thaler², Danieli Andrade³, Megan Barber⁴, Maria Tektonidou⁵, Savino Sciascia⁶, Vittorio Pengo⁷, Jose Pardos-Gea⁸, Guillermo Ruiz-Irastorza⁹, Chary Lopez-Pedrera¹⁰, H Michael Belmont¹¹, Kello Nina¹², Paul R. Fortin¹³, Stéphane Zuily¹⁴, Cecilia Chighizola¹⁵, Flavio Victor Signorelli¹⁶, Zhuoli Zhang¹⁷, Tatsuya Atsuma¹⁸, Maria Efthymiou¹⁹, D. Ware Branch²⁰, Cecilia Nalli²¹, Esther Rodriguez almaraz²², Michelle Petri²³, Giulia Pazzola²⁴, Ricard Cervera²⁵, Bahar Artim Esen²⁶, Hui Shi²⁷, Yu Zuo²⁸, Rosana M Quintana²⁹, Rohan Willis³⁰, Ali Duarte-Garcia³¹, Maria Laura Bertolaccini³², Hannah Cohen³³, Doruk Erkan² and On Behalf Of APS ACTION³⁴, ¹SUNY Downstate Medical Center, Brooklyn, NY, ²Hospital for Special Surgery, New York, NY, ³University of São Paulo, São Paulo, Brazil, ⁴University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada, ⁵Joint Academic Rheumatology Program, First Department of Propedeutic and Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece, ⁶University of Turin, Torino, Italy, ⁷Department of Cardiac-Thoracic-Vascular Sciences and Public Health University of Padova, Padova, Italy, ⁸Vall d'Hebron University Hospital, Barcelona, Spain, ⁹Hospital Universitario Cruces, Barakaldo, Spain, ¹⁰IMIBIC - Reina Sofia Hospital, Córdoba, Spain, ¹¹NYU School of Medicine, New York, NY, ¹²Northwell Health, Brooklyn, NY, ¹³Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada, ¹⁴Lorraine University, Vandoeuvre-lès-Nancy, France, ¹⁵University of Milan, Milan, Italy, ¹⁶University of São Paulo, Rio De Janeiro, Brazil, ¹⁷Peking University First Hospital, Rheumatology and Immunology Department, Beijing, China, ¹⁸Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Sapporo, Japan, ¹⁹University College London, London, United Kingdom, ²⁰University of Utah, Salt Lake City, UT, ²¹Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, ²²Hospital Universitario 12 de Octubre, Madrid, Spain, ²³Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ²⁴Azienda Ospedaliera Santa Maria Nuova di Reggio Emilia, Reggio Emilia, Italy, ²⁵Hospital Clínic de Barcelona, Barcelona, Spain, ²⁶Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²⁷Rijin Hospital, Shanghai, China, ²⁸University of Michigan, Ann Arbor, MI, ²⁹Centro Regional de Enfermedades Autoinmunes y Reumticas (CREAR), Grupo Oroño, Rosario, Argentina, ³⁰University of Texas Medical Branch, Galveston, TX, ³¹Mayo Clinic, Rochester, MN, ³²King's College London, London, United Kingdom, ³³University College London Hospitals NHS Foundation Trust, London, United Kingdom, ³⁴on behalf of APS ACTION, New York, NY
Background/Purpose: APS ACTION Registry aims to study the course of disease in antiphospholipid antibody (aPL)-positive patients. Although transient ischemic attack (TIA) can develop in aPL-positive…
Abstract Number: 0113 • ACR Convergence 2023
Serum Myeloperoxidase (MPO)-DNA Complexes and Serum Calprotectin Differentiate Isolated Thrombotic Antiphospholipid Syndrome from Isolated Obstetric Antiphospholipid Syndrome
Ruyu Liang¹, Ranran Yao², Ziye Wang³, Wenwen Pei², Renge Liang³ and Chun Li⁴, ¹Peking University, XiCheng, China, ²Peking University, Beijing, China, ³Peking University People's Hospital, Beijing, China, ⁴Peking University People’s Hospital, Beijing, China
Background/Purpose: There is a lack of serum markers to differentiate thrombotic APS (tAPS) and obstetric APS (oAPS). Neutrophil extracellular traps (NETs) are involved in the…
Abstract Number: 2454 • ACR Convergence 2023
Endometriosis Increase Risk of Antiphospholipid Syndrome: A Propensity Score Matched Cohort Study
Zhiyong Chen¹, Shiow-Ing Wang², James Cheng-Chung Wei³ and Sheng-Ming Dai¹, ¹Department of Rheumatology and Immunology, Shanghai Sixth People’s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, ²Institute of Medicine, College of Medicine, Chung Shan Medical University, Taichung, Taiwan, ³Chung Shan Medical University Hospital, Department of Rheumatology, Taichung, Taiwan
Background/Purpose: Patients with endometriosis have a variety of autoimmune abnormalities. Our objective was to investigate the risk of incident antiphospholipid syndrome (APS) in patients with…
Abstract Number: 0098 • ACR Convergence 2023
Predictors of Mortality in Antiphospholipid Antibody Positive Patients: Prospective Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository “Registry”
Yasaman Ahmadzadeh¹, Larry Magder², Zeynep Ozge Ozdemir³, Danieli Andrade⁴, Megan R.W. Barber⁵, Maria Tektonidou⁶, Savino Sciascia⁷, Vittorio Pengo⁸, Ariadna Anunciación-Llunell⁹, Guillermo Ruiz-Irastorza¹⁰, Mª Angeles Aguirre¹¹, Michael Belmont¹², Kello Nina¹³, Paul R. Fortin¹⁴, Denis WAHL¹⁵, Maria Gerosa¹⁶, Guilherme De Jesús¹⁷, Zhuoli Zhang¹⁸, Tatsuya Atsuma¹⁹, Maria Efthymiou²⁰, D. Ware Branch²¹, Angela Tincani²², Esther Rodriguez almaraz²³, Giulia Pazzola²⁴, Ricard Cervera²⁵, Bahar Artim Esen²⁶, Hui Shi²⁷, Jason Knight²⁸, Guillermo Pons-Estel²⁹, Rohan Willis³⁰, Ali Duarte-Garcia³¹, Maria Laura Bertolaccini³², Hannah Cohen³³, Michelle Petri³⁴, Doruk Erkan³⁵ and On Behalf Of APS ACTION³⁶, ¹Roger Williams Medical Center, Providence, RI, ²University of Maryland, Baltimore, MD, ³Hacettepe University Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey, ⁴University of São Paulo, São Paulo, Brazil, ⁵University of Calgary, Calgary, AB, Canada, ⁶Joint Academic Rheumatology Program, First Department of Propedeutic and Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece, ⁷University of Turin, Torino, Italy, ⁸Department of Cardiac-Thoracic-Vascular Sciences and Public Health University of Padova, Padova, Italy, ⁹VHIR Vall d'Hebron Institut de Investigación, Barcelona, Spain, ¹⁰Hospital Universitario Cruces, Barakaldo, Spain, ¹¹Reina Sofía University Hospital/ Rheumatology Department, Córdoba, Spain, ¹²New York University Langone Medical Center, New York, NY, ¹³Northwell Health, Brooklyn, NY, ¹⁴Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada, ¹⁵University of Lorraine, Nancy, France, ¹⁶University of Milan, Milano, Italy, ¹⁷Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, ¹⁸Peking University First Hospital, Rheumatology and Immunology Department, Beijing, China, ¹⁹Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Sapporo, Japan, ²⁰University College London, London, United Kingdom, ²¹University of Utah, Salt Lake City, UT, ²²Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, University of Brescia, Gussago, Italy, ²³Hospital Universitario 12 de Octubre, Madrid, Spain, ²⁴Azienda Ospedaliera Santa Maria Nuova di Reggio Emilia, Reggio Emilia, Italy, ²⁵Hospital Clínic de Barcelona, Barcelona, Spain, ²⁶Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²⁷Rijin Hospital, Shanghai, China, ²⁸University of Michigan, Ann Arbor, MI, ²⁹CREAR, Rosario, Argentina, ³⁰University of Texas Medical Branch, Galveston, TX, ³¹Mayo Clinic, Rochester, MN, ³²King's College London, London, United Kingdom, ³³Haemostasis Research Unit, Department of Hematology, University College London, London, United Kingdom, ³⁴Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ³⁵Hospital for Special Surgery, New York, NY, ³⁶on behalf of APS ACTION, New York, NY
Background/Purpose: APS ACTION "Registry" was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL)-positive patients with/without other systemic…
Abstract Number: 0114 • ACR Convergence 2023
Platelets Are Highly Activated and Could Participate in Immune Abnormality of APS
Yu Shi¹, Xiaofan Luo², Quan Chen³, Jiuliang zhao⁴, Mengtao Li⁴ and xiaofeng Zeng⁵, ¹Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ²Nankai University, Tianjin, China, ³Nankai University, Beijing, China, ⁴Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁵Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Background/Purpose: Platelets play a pivotal role in the process of coagulation and other biological process. Studies have shown multiple evidences that platelets are highly activated…
Abstract Number: 0099 • ACR Convergence 2023
Cell-bound Complement Activation Products in Antiphospholipid Antibody-positive Patients Without Other Systemic Autoimmune Diseases
Doruk Erkan¹, JoAnn Vega¹, Tyler O'Malley² and Andrew Concoff³, ¹Hospital for Special Surgery, New York, NY, ²Exagen, Vista, CA, ³Exagen, Los Angeles, CA
Background/Purpose: Based on animal models, complement activation is part of Antiphospholipid Syndrome (APS) pathogenesis. However, studies investigating complement activation in antiphospholipid antibody (aPL)-positive patients are…
Abstract Number: 0115 • ACR Convergence 2023
Risk Factors of First Thrombosis in Obstetric Antiphospholipid Syndrome
liang luo¹, Qingmeng Cai², xiangjun liu², Yuke Hou³ and Chun Li⁴, ¹Department of Chinese Medicine, the People's Hospital of Yubei District of Chongqing City, Chongqing, China; Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ²Department of Rheumatology and Immunology, Peking University People's Hospital, Xicheng District, Beijing, China, ³Peking University People's Hospital, Beijing, China, ⁴Peking University People’s Hospital, Beijing, China
Background/Purpose: Limited evidence exists regarding the long-term risk of thrombosis in patients with obstetric antiphospholipid syndrome (OAPS). This study aimed to investigate the clinical features…
Abstract Number: 0100 • ACR Convergence 2023
The Clinical Relevance of Different Antiphospholipid Antibody Profiles in Pediatric Rheumatology Patients
Jheel Pandya, Karen Onel and Doruk Erkan, Hospital for Special Surgery, New York, NY
Background/Purpose: The clinical relevance of different antiphospholipid antibody (aPL) profiles, including low level anticardiolipin (aCL) and anti β2-glycoprotein-I (aβ2GPI) antibodies, is ill-defined in the pediatric…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].